Executive leadership at OSR Holdings.
Board of directors at OSR Holdings.
Research analysts covering OSR Holdings.
Recent press releases and 8-K filings for OSRH.
OSR Holdings Completes Woori IO Acquisition and Reviews Medical Device Subsidiary Combination
OSRH
M&A
New Projects/Investments
- OSR Holdings, Inc. (OSRH) officially closed its acquisition of Woori IO on January 26, 2026, making Woori IO a consolidated subsidiary.
- Historical shareholders of Woori IO have committed to a three-year equity alignment, agreeing to exchange their interests into OSRH common stock at a reference price of $10.00 per share.
- OSRH is conducting a strategic review for a potential combination of its medical device subsidiaries, Woori IO and RMC, with the aim of forming an integrated medical technology and distribution company that could potentially support a standalone IPO in Korea.
- The acquisition of Woori IO was completed through the issuance of equity interests of OSRK, an OSRH subsidiary, and no shares of OSRH's common stock were issued in the transaction.
Jan 27, 2026, 2:26 PM
OSR Holdings' Woori IO Accelerates Commercial Launch Following FDA Clarification
OSRH
Product Launch
New Projects/Investments
M&A
- Woori IO, an OSR Holdings company, is accelerating its commercialization of noninvasive glucose monitoring wearables due to a recent FDA clarification.
- The FDA's guidance indicates that non-medical, wellness-oriented wearables generally fall outside medical device pre-market review, allowing Woori IO to expedite market entry with consumer-grade products.
- Woori IO will pursue a two-phase commercialization strategy, initially launching consumer wellness wearables and subsequently developing medical-grade Continuous Glucose Monitoring (CGM) solutions.
- This accelerated roadmap supports OSR Holdings' broader digital health strategy, with the share exchange transaction expected to complete on January 26, 2026.
Jan 22, 2026, 2:55 PM
OSR Holdings' Subsidiary Vaximm Receives Binding Term Sheet for VXM01 Global License
OSRH
New Projects/Investments
M&A
- OSR Holdings, Inc. announced that its subsidiary, Vaximm AG, received a binding term sheet from BCM Europe AG, the largest shareholder of OSR Holdings, for a global exclusive license of VXM01, Vaximm’s lead immunotherapy candidate.
- The agreement includes an upfront payment of $30 million, comprising $15 million in cash and $15 million in digital assets, along with up to $815 million in aggregate clinical, regulatory, and commercial milestone payments.
- The parties aim to finalize a definitive agreement by the end of May 2026, contingent on customary conditions, including an independent third-party fairness opinion given the related-party nature of the transaction.
Jan 14, 2026, 2:27 PM
OSR Holdings' Vaximm Subsidiary Receives Binding Term Sheet for VXM01 Licensing
OSRH
New Projects/Investments
- OSR Holdings' Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG for a global exclusive licensing transaction for its lead immunotherapy candidate, VXM01.
- The proposed agreement includes an upfront payment of $30 million, structured as 50% cash and 50% digital assets, and potential aggregate milestone payments of up to $815 million.
- A definitive agreement is targeted for execution by the end of May 2026, subject to Vaximm's board review, an independent fairness opinion, and other customary conditions.
Jan 12, 2026, 1:05 PM
OSR Holdings Completes Acquisition of Woori IO, Advancing Glucose Monitoring Technology
OSRH
M&A
New Projects/Investments
Product Launch
- OSR Holdings, Inc. announced that Woori IO Co., Ltd. shareholders approved a share exchange, making Woori IO a wholly-owned subsidiary of OSRK, OSR Holdings' Korean intermediate holding company.
- Woori IO, a developer of noninvasive glucose monitoring technology, is collaborating with Samsung Electronics on a Proof-of-Concept study in South Korea for regulatory approval.
- The company also plans to initiate U.S. market development and a U.S. FDA clinical trial for its technology through a collaboration with a research university.
Dec 19, 2025, 4:50 PM
OSR Holdings' Vaximm AG Updates Term Sheet for VXM01 Licensing Agreement
OSRH
New Projects/Investments
- OSR Holdings' subsidiary, Vaximm AG, and BCM Europe AG (BCME) have shortened the exclusivity period for their non-binding term sheet from six months to three months, with the expectation to finalize a definitive global licensing agreement for VXM01 by February 2026.
- The financial terms for the potential licensing agreement remain unchanged, including a $20 million upfront payment to Vaximm and up to $815 million in clinical, regulatory, and commercial milestone payments.
- This accelerated timeline reflects confidence in BCME's ability to efficiently mobilize capital and advance due diligence to position VXM01 for a major pharmaceutical partnership.
Dec 2, 2025, 2:53 PM
OSR Holdings' Subsidiary Vaximm AG Enters Term Sheet for VXM01 License
OSRH
New Projects/Investments
- OSR Holdings, Inc.'s subsidiary, Vaximm AG, entered into a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement for its VXM01 oral cancer immunotherapy platform.
- The agreement, dated November 21, 2025, includes a contemplated $20 million upfront payment and up to $815 million in clinical, regulatory, and commercial milestone payments to Vaximm.
- BCM Europe AG will act as a strategic financial intermediary, funding development and partnering activities to secure a global out-license with a major pharmaceutical company.
- The term sheet grants BCM Europe AG an exclusive 120-day period to finalize the definitive agreement.
Nov 25, 2025, 3:56 PM
OSR Holdings' Vaximm AG Enters Term Sheet for VXM01 License
OSRH
New Projects/Investments
- Vaximm AG, a subsidiary of OSR Holdings, has entered a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement for VXM01, its oral cancer immunotherapy platform.
- The proposed agreement includes a $20 million upfront payment and up to $815 million in clinical, regulatory, and commercial milestone payments to Vaximm.
- BCM Europe AG, OSRH's largest shareholder, would fund the partnering and development activities for VXM01 during a six-month exclusivity period.
- Vaximm will retain full ownership of its VXM01 intellectual property.
Nov 21, 2025, 2:20 PM
OSR Holdings Appoints Dr. Andreas Niethammer as CEO of Vaximm AG
OSRH
Management Change
New Projects/Investments
- OSR Holdings, Inc. announced the appointment of Dr. Andreas Niethammer as Chief Executive Officer (CEO) of its subsidiary, Vaximm AG, effective December 1, 2025.
- Dr. Niethammer, Vaximm's scientific co-founder and Chief Medical Officer, will lead the integration of Vaximm's immune activation platform with viral oncolysis technologies through a forthcoming strategic collaboration.
- This collaboration aims to build a next-generation immuno-oncology platform targeting renal cell carcinoma (RCC) and other advanced solid tumors.
Nov 14, 2025, 4:10 PM
OSR Holdings, Inc. to Acquire Woori IO, a Non-Invasive Glucose Monitoring Company
OSRH
M&A
New Projects/Investments
- OSR Holdings, Inc. (OSRH) has signed a definitive agreement to acquire Woori IO Co., Ltd. (WORIO), a South Korea-based medical-device company specializing in non-invasive glucose monitoring (NIGM) technology, for approximately KRW15bn (~$10.5 million).
- The acquisition is structured such that WORIO will become a wholly owned subsidiary of OSRH's Korean affiliate, OSR Holdings Co., Ltd. (OSRK), with former WORIO shareholders receiving OSRK shares.
- A key condition allows former WORIO shareholders to exchange their OSRK shares for 1,093,020 newly issued OSRH common shares at a ratio of 12.96 OSRH shares for each OSRK share, if OSRH's NASDAQ share price reaches $10.00 within three years of the share exchange.
- This strategic move aims to strengthen OSRH's medical-device platform and diversify its healthcare portfolio, tapping into the global glucose-monitoring market projected to exceed $40 billion by 2030. The transaction is expected to be effective on January 12, 2026, pending WORIO shareholder approval by December 19, 2025.
Oct 16, 2025, 3:10 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more